Abstract
ABSTRACTVoriconazole is a first-line agent for the treatment of invasive fungal infections. The pharmacology of voriconazole is characterized by extensive interindividual variability and nonlinear pharmacokinetics. The population pharmacokinetics of voriconazole in 64 adults is described. The patient population consisted of 21 healthy volunteers, who received a range of intravenous (i.v.) and oral voriconazole regimens, and 43 patients with proven or probable invasive aspergillosis, who received the currently licensed dosage. Voriconazole concentrations were measured using high-performance liquid chromatography (HPLC). The pharmacokinetic data were modeled using a nonparametric methodology and with a nonlinear pharmacokinetic structural model. The extent and consequences of pharmacokinetic variability were explored using Monte Carlo simulation. The relationship between drug exposure and clinical response was explored using logistic regression. Optimal sampling times were identified using D-optimal design. The fit of the nonlinear model was acceptable. Data from the healthy volunteers provided robust estimates forKmand the maximum rate of enzyme activity (Vmax). The Bayesian parameter estimates were more variable and statistically different in patients than in volunteers. There was a linear relationship between the trough concentration and area under the concentration-time curve (AUC0-12). There was no relationship between the AUC0-12and clinical response. The original parameter values were readily recapitulated using Monte Carlo simulation. Initial i.v. dosing resulted in higher AUC0-12and trough concentrations compared with oral dosing. Sample collection times of 1, 2, 3, 4, 8, and 12 h after an i.v. infusion are maximally informative times for future pharmacokinetic studies.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference14 articles.
1. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software;D'Argenio,2009
2. FDA Antiviral Drugs Advisory Committee. 2001. Briefing document for voriconazole (oral and intravenous formulations). www.fda.gov/ohrms/dockets/AC/01/briefing/3792b2_01_Pfizer.pdf.
3. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis;Herbrecht;N. Engl. J. Med,2002
4. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies;Karlsson;Antimicrob. Agents Chemother,2009
5. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models;Leary,2001
Cited by
83 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献